ArticlePathogens (Basel, Switzerland)2022

GMP Manufacturing and IND-Enabling Studies of a Recombinant Hyperimmune Globulin Targeting SARS-CoV-2.

Rena A Mizrahi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.